Connect
← Return to Aromatase Inhibitors: Did you decide to go on them or not?
Discussion
Aromatase Inhibitors: Did you decide to go on them or not?
Breast Cancer | Last Active: May 12, 2023 | Replies (1190)Comment receiving replies
ps The Tailor X study was to help women with intermediate Oncotype DX scores decide on whether to have chemo or not. Low scores and high scores had a more clear path.
"Women in the trial who had a score in the intermediate range (11–25) were randomly assigned to receive hormone therapy alone or hormone therapy with adjuvant chemotherapy. The goal was to assess whether women who received hormone therapy alone had outcomes that were as good as those among women who received chemotherapy in addition to hormone therapy." https://www.cancer.gov/news-events/press-releases/2018/tailorx-breast-cancer-chemotherapy
The study supported the use of hormonal meds only, without chemo, for these patients. "According to the authors, the new findings suggest that chemotherapy may be avoided in about 70 percent of women with HR-positive, HER2-negative, node-negative breast cancer." All participants were on hormonal meds.
Replies to "ps The Tailor X study was to help women with intermediate Oncotype DX scores decide on..."
Connect
Yes, correct. Though I thought that the Tailor X had a broader scope and Oncotype later used select data for its arm of its own data pool. OncotypeDX is, as the scientist there noted, the only test they currently offer with respect to breast cancer that is both predictive and prognostic. And none of their current tests are designed to help make treatment decisions about radiology for breast cancer.
I wish there were a test to determine how likely an individual's body would actually benefit from SERMs or AIs based on the genetics and general health and other clinical data. If we could each have that assurance, I think a lot more women would tolerate uneasy side effects because they can quantify the payoff in confidence. Alas, medical science isn't there yet but I'm very grateful that genetic tests are becoming increasingly sophisticated and available.